GBA3 as a regulator of sphingolipid metabolism in the progression of hepatocellular carcinoma.

ABSTRACT:

Background

The prognosis and clinical treatment of hepatocellular carcinoma (HCC), one of the most prevalent malignant tumors, remains significantly challenging, underscoring the urgent need for novel biomarkers and therapeutic strategies to improve patient outcomes. Our study investigated the clinical significance and biological functions of glucosylceramidase beta 3 (GBA3) in HCC progression.

Methods

GBA3 expression was analyzed in 39 paired HCC and adjacent non-tumor tissues, validated in The Cancer Genome Atlas (TCGA) dataset, and further confirmed via immunohistochemistry (IHC) in 90 additional paired specimens. The connection between GBA3 expression and clinical outcomes was analyzed through use of TCGA data and Kaplan-Meier survival analysis. The functional roles of G

SUBMITTER: Wang X 

PROVIDER: S-EPMC12432923 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature